Clinical and histological characteristics of rapidly progressive glomerulonephritis in patients treated at a general hospital
Abstract
Introduction: Assessing the clinical and histological characteristics of patients with rapidly progressive glomerulonephritis (RPGN) treated at a General Hospital. Methods: The kidney biopsies conducted at Hospital Nacional Arzobispo Loayza between 1998 and 2008 were evaluated. RPGN was histologically determined when the biopsy had more than 50% of epithelial crescents. The following information was recorded: age, gender, kidney syndrome present (kidney failure, nephritic syndrome, nephrotic syndrome, arterial hypertension); immune parameters (antinuclear antibodies, anti DNA antibodies, ANCA, complement 3, anti GBM antibodies and ESR) and histological parameters (epithelial or fibroepithelial crescent percentage, interstitial infiltrates and tubular atrophy). In order to describe the results, measures of central tendency and standard deviation were used. Results: RPGN accounted for 2.72% of kidney biopsies. The average age was 33.77 ± 11.7 years. The ave rage creatinine at entry was 4.5 ± 4.8 (0.5 –26.0) mg/dl. There was a 59.3% of patients with HTN; 48.1% had nephrotic syndrome and 48.1% had nephritic syndrome. There was a 52.7% of ANCA-positive cases, and 60% experienced C3 decrease. The crescent percentage was 71.2%. The interstitial infiltrate and the tubular atrophy were mild in 63 and 74% of the patients, respectively. The most frequent causes for RPGN were systemic lupus erythematosus (44.4%) and vasculitis (37%). Average length of stay in hospital was 30 days. A 51.8% of the patients required hemodialysis and 33% continued with hemodialysis upon discharge. Conclusions: RPGN is a rare disease at our hospital, and the most frequent cause for it was SLE.
References
Markowitz GS, Radhakrishnan J, D'Agati VD. An overlapping etiology of rapidly progressive glomerulonephritis. Am J Kidney Dis. 2004;43(2):388-93.
Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63(3):1164-77.
Anders HJ. Diagnosis and management of crescentic glomerulonephritis: state of the art. Saudi J Kidney Dis Transpl. 2000;11(3):353-61.
Jindal KK. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl. 1999;70:S33-40.
Jennette JC, Thomas DB. Crescentic glomerulonephritis. Nephrol Dial Transplant. 2001;16 Suppl 6:80-2.
Brenner & Rector’s The kidney. Barry M. Brenner ed. 5th ed. Philadelphia : Saunders, 1996, p. 1405.
Hedger N, Stevens J, Drey N, Walker S, Roderick P. Incidence and outcome of pauci-immune rapidly progressive glomerulonephritis in Wessex, UK: a 10-year retrospective study. Nephrol Dial Transplant. 2000;15(10):1593-9.
Jennette JC, Falk RJ. The pathology of vasculitis involving the kidney. Am J Kidney Dis. 1994;24(1):130-41.
Haas M, Spargo BH, Wit EJ, Meehan SM. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis. 2000;35(3):433-47.
Nair R, Bell JM, Walker PD. Renal biopsy in patients aged 80 years and older. Am J Kidney Dis. 2004;44(4):618-26.
Tang Z, Wu Y, Wang Q, Zeng C, Yao X, Hu W, et al. Clinical spectrum of diffuse crescentic glomerulonephritis in Chinese patients. Chin Med J.
;116(11):1737-40.
Saxena R, Mahajan T, Mohan C. Lupus nephritis: current update. Arthritis Res Ther. 2011;13(5):240.
Masani NN, Imbriano LJ, D'Agati VD, Markowitz GS. SLE and rapidly progressive glomerulonephritis. Am J Kidney Dis. 2005;45(5):950-5.
Sumethkul V, Chalermsanyakorn P, Changsirikulchai S, Radinahamed P. Lupus nephritis: a challenging cause of rapidly progressive crescentic glomerulonephritis. Lupus. 2000;9(6):424-8.
Yu F, Tan Y, Liu G, Wang SX, Zou WZ, Zhao MH. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int. 2009;76(3):307-17.
Nasr SH, D'Agati VD, Park HR, Sterman PL, Goyzueta JD, Dressler RM, et al. Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol. 2008;3(3):682-90.
Hubner J. Glomerulonefritis crescéntica (rápidamente progresiva) en el Hospital Arzobispo Loayza: estudio clínico patológico de 14 casos. Tesis para optar al grado de especialista en Nefrología. Lima, Perú. Universidad Peruana Cayetano Heredia, 1985. 24 p.
Kannan S, Mattoo TK. Diffuse crescentic glomerulonephritis in bacterial endocarditis. Pediatr Nephrol. 2001;16(5):423-8.
Osafune K, Takeoka H, Kanamori H, Koshiyama K, Hirose M, Hanada R, et al. Crescentic glomerulonephritis associated with infective endocarditis: renal recovery after immediate surgical intervention. Clin Exp Nephrol. 2000;4(4):329-34.
Haseyama T, Imai H, Komatsuda A, Hamai K, Ohtani H, Kibira S, et al. Proteinase-3-antineutrophil cytoplasmic antibody (PR3-ANCA) positive crescentic glomerulonephritis in a patient with Down's syndrome and infectious endocarditis. Nephrol Dial Transplant. 1998;13(8):2142-6.
Chen M, Yu F, Wang SX, Zou WZ, Zhao MH, Wang HY. Antineutrophil cytoplasmic autoantibody-negative Pauci-immune crescentic glomerulonephritis. J Am Soc Nephrol. 2007;18(2):599-605.
Kaplan-Pavlovcic S, Cerk K, Kveder R, Lindic J, Vizjak A. Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant. 2003;18(Suppl 5):v5-7.
Eisenberger U, Fakhouri F, Vanhille P, Beaufils H, Mahr A, Guillevin L, et al. ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant. 2005;20(7):1392-9.
Rutgers A, Slot M, Van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert JW. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis. 2005;46(2):253-62.
Jayne DR, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. 1990;37(3):965-70.
Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66(4):1535-40.
